NDAORALTABLET
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
ZYPITAMAG (pitavastatin magnesium) by Medicure is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for hmg-coa reductase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPITAMAG is an oral tablet containing pitavastatin magnesium, an HMG-CoA reductase inhibitor (statin) approved in 2017. It reduces cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver. ZYPITAMAG is indicated for patients with elevated cholesterol levels who require lipid-lowering therapy.
$0.004BPart D
Peak4.7 years to LOEZYPITAMAG is in peak commercial phase with modest Part D uptake; the brand team is likely stable but faces significant generic statin competition limiting growth potential.
Mechanism of Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Class:
HMG-CoA Reductase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on ZYPITAMAG at Medicure? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.